353 related articles for article (PubMed ID: 9114437)
1. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
3. Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory JG; Cory AH; Lorico A; Rappa G; Sartorelli AC
Anticancer Res; 1997; 17(5A):3185-93. PubMed ID: 9413147
[TBL] [Abstract][Full Text] [Related]
4. Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
Crenshaw TR; Cory JG
Int J Oncol; 1999 Sep; 15(3):487-90. PubMed ID: 10427129
[TBL] [Abstract][Full Text] [Related]
5. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
6. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Somerville L; Cory AH; Cory JG
In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
[TBL] [Abstract][Full Text] [Related]
7. Liver microsomal inactivation of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone as an inhibitor of ribonucleotide reductase.
Williams MT; Simonet L; Cory AH; Cory JG
Cancer Res; 1988 Nov; 48(22):6375-8. PubMed ID: 3052801
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC
Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341
[TBL] [Abstract][Full Text] [Related]
9. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
[TBL] [Abstract][Full Text] [Related]
10. Changes in messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells.
Thompson DP; Carter GL; Cory JG
Cancer Commun; 1989; 1(4):253-60. PubMed ID: 2700914
[TBL] [Abstract][Full Text] [Related]
11. 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a second-generation antineoplastic agent of the alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone series.
Agrawal KC; Schenkman JB; Denk H; Mooney PD; Moore EC; Wodinsky I; Sartorelli AC
Cancer Res; 1977 Jun; 37(6):1692-6. PubMed ID: 870183
[TBL] [Abstract][Full Text] [Related]
12. Relationships between sensitivity to hydroxyurea and 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIO) and ribonucleotide reductase RNR2 mRNA levels in strains of Saccharomyces cerevisiae.
Rittberg DA; Wright JA
Biochem Cell Biol; 1989 Jul; 67(7):352-7. PubMed ID: 2675933
[TBL] [Abstract][Full Text] [Related]
13. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
14. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
15. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
Choy BK; McClarty GA; Chan AK; Thelander L; Wright JA
Cancer Res; 1988 Apr; 48(8):2029-35. PubMed ID: 2832057
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
18. [Biochemical mechanisms of resistance to a new antineoplastic drug CRC 680578 from the nitrosourea class].
Gudtsova KV; Kukushkina GV; Gorbacheva LB
Biokhimiia; 1991 Aug; 56(8):1509-21. PubMed ID: 1782268
[TBL] [Abstract][Full Text] [Related]
19. Effects of the ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ-1) on the kinetics of reduction of CDP by ribonucleotide reductase of the Novikoff tumor.
Preidecker PJ; Agrawal KC; Sartorelli AC; Moore EC
Mol Pharmacol; 1980 Nov; 18(3):507-12. PubMed ID: 7007866
[No Abstract] [Full Text] [Related]
20. Specific inhibitors directed at the individual components of ribonucleotide reductase as an approach to combination chemotherapy.
Cory JG; Fleischer AE
Cancer Res; 1979 Nov; 39(11):4600-4. PubMed ID: 498090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
